Avenue Therapeutics AI Stock Analysis
Want to see ATXI full AI Analyst Report?
Avenue Therapeutics (ATXI) AI Stock Analysis
Avenue Therapeutics
(Other OTC:ATXI)
The score is driven primarily by severe financial weakness, including no revenue, negative equity, and ongoing cash burn. Bearish technical positioning and the absence of valuation support reinforce the highly speculative profile, despite oversold momentum readings.
Avenue Therapeutics (ATXI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,934
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.99
- Revenue Growth
- -100.00%
- EPS Growth
- 42.53%
- Country
- US
- Employees
- 1
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Avenue Therapeutics Business Overview & Revenue Model
Company Description
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product c...
How the Company Makes Money
Avenue Therapeutics’ ability to generate revenue is primarily tied to monetizing its drug-development programs rather than diversified operating businesses. In general, the company can make money through (i) collaboration, licensing, or commercializa...
Avenue Therapeutics Financial Statement Overview
Summary
Very weak performance: zero revenue, recurring losses, negative TTM equity, and continued cash burn. Debt-free status and reduced losses provide limited support.
Income Statement
7Very NegativeBalance Sheet
24NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 1.40M | 0 | 0 | 0 | 0 |
| Gross Profit | -1.40M | 1.40M | 0 | 0 | 0 | 0 |
| EBITDA | -3.08M | -3.29M | -11.70M | 4.05M | -2.44M | 7,000 |
| Net Income | -2.79M | -2.91M | -11.65M | -10.38M | -3.55M | -3.73M |
Balance Sheet | ||||||
| Total Assets | 1.53M | 2.93M | 2.67M | 1.85M | 6.84M | 3.96M |
| Cash, Cash Equivalents and Short-Term Investments | 1.52M | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.60M | 1.10M | 816.00K | 1.20M | 3.58M | 509.00K |
| Stockholders Equity | -75.00K | 1.83M | 2.80M | 1.58M | 3.90M | 3.45M |
Cash Flow | ||||||
| Free Cash Flow | -2.19M | -1.83M | -9.03M | -12.45M | -7.60M | -3.75M |
| Operating Cash Flow | -2.19M | -1.83M | -9.03M | -9.45M | -7.60M | -3.75M |
| Investing Cash Flow | 0 | 0 | 0 | -3.00M | 0 | 0 |
| Financing Cash Flow | 0 | 2.09M | 9.84M | 7.53M | 10.54M | 4.38M |
Avenue Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.44, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.31 is Neutral, neither overbought nor oversold. The STOCH value of 4.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATXI.
Avenue Therapeutics Risk Analysis
Avenue Therapeutics disclosed 65 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAvenue Therapeutics Peers Comparison
Overall Rating
ADXN44Neutral
CTXR43Neutral
ENSC40Underperform
SKYE40Underperform
CALC39Underperform
ATXI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 44Neutral | $4.89M | -0.69 | -172.76% | ― | -45.76% | -3.77% | |
| 43Neutral | $14.69M | -0.25 | -67.15% | ― | ― | 57.48% | |
| 40Underperform | $8.14M | -0.07 | -1232.64% | ― | 37.91% | 1.72% | |
| 40Underperform | $4.83M | -0.14 | -503.95% | ― | ― | 26.40% | |
| 39Underperform | $8.34M | -0.27 | -3029.57% | ― | ― | 45.29% | |
| 38Underperform | $922.59K | -0.33 | -316.12% | ― | -100.00% | 42.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ATXI | Avenue Therapeutics | 0.28 | -0.52 | -65.00% | |
| ENSC | Ensysce Biosciences, Inc. | 0.42 | -1.54 | -78.67% | |
| CTXR | Citius Pharma | 0.54 | -0.40 | -42.78% | |
| SKYE | Skye Bioscience, Inc. | 1.09 | -10.11 | -90.27% | |
| CALC | Calcimedica, Inc. | 1.21 | -14.51 | -92.30% | |
| ADXN | Addex Therapeutics Ltd (ADR) | 4.06 | -4.34 | -51.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
